Results 81 to 90 of about 3,331 (189)

Effect of menopausal hormone therapy on the skin as a component of healthy aging

Медицинский совет, 2018
Healthy aging (anti-aging) involves the prevention of illness and disability, keeping mental and physical activity in tip-top shape, maintaining the meaning and purpose of life. Women refuse to age and want to look younger as long as possible.
S. V. Yureneva, L. M. Ilyina
doaj   +1 more source

Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone : results of three multicentre trials

, 2009
The ethinylestradiol 20 mug/drospirenone 3 mg combined oral contraceptive (COC), administered in cycles of 21 days continuous use followed by a 7-day hormone-free interval (21/7) [Yasminelle((R))], has been proven to be an effective and well tolerated ...
BITZER J, Paoletti, Anna M., Bitzer, Johannes, PAOLETTI, ANNA MARIA   +3 more
core   +1 more source

Efficacy and safety of ultralow doses of drospirenone and 17β-estradiol in postmenopausal women meta-analysis

Медицинский совет, 2018
Vasomotor symptoms, including hot flashes (HF), are the most common symptoms of the menopause, which require the hormone replacement therapy with estrogens and/or progestogens. Recent international clinical guidelines recognize the need to use the lowest
O. R. Grigoryan
doaj   +1 more source

A Comparative Investigation of Contraceptive Reliability, Cycle Control and Tolerance of Two Monophasic Oral Contraceptives Containing Either Drospirenone or Desogestrel

, 2000
peer reviewedOBJECTIVE: To assess the contraceptive reliability, cycle control and tolerance of a new monophasic oral contraceptive (Yasmin) containing 30 microg ethinylestradiol and 3 mg drospirenone and compare it with a preparation containing an equal
Wuttke, W., Heithecker, R., Foidart, Jean-Michel, Bouw, G. M., Gerlinger, C.   +4 more
core   +1 more source

Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder

International Journal of Women's Health, 2009
Lesley L Breech, Paula K BravermanDivision of Adolescent Medicine, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USAAbstract: Premenstrual dysphoric ...
Lesley L Breech, Paula K Braverman
doaj  

Hormone withdrawal-associated symptoms with ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 µg/desogestrel 150 µg (21/7 regimen)

International Journal of Women's Health, 2015
Johannes Bitzer,1 Maria Jesusa Banal-Silao,2 Hans-Joachim Ahrendt,3 Jaime Restrepo,4 Marion Hardtke,5 Ulrike Wissinger-Graefenhahn,6 Dietmar Trummer7 1Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland; 2University ...
Bitzer J, Banal-Silao MJ, Ahrendt HJ, Restrepo J, Hardtke M, Wissinger-Graefenhahn U, Trummer D   +6 more
doaj  

Drospirenone and PCOS [PDF]

Journal of Family Planning and Reproductive Health Care, 2005
openaire   +2 more sources

Safety and tolerability of a combined oral contraceptive containing estetrol/drospirenone in real-life clinical practice: An open-label, prospective, multicenter, epidemiological, observational program "Estetiko"

Гинекология
Aim. To evaluate the safety and acceptability of a combined oral contraceptive (COC) containing estetrol 15 mg and drospirenone 3 mg when taken for 6 cycles in real clinical practice. Materials and methods. An open-label prospective multicenter (in 20
Natalia V. Aganezova, Rushania I. Gabidullina   +1 more
doaj   +1 more source

Metabolic profile dynamics and cardiovascular risk markers in normal- and overweight women of reproductive age taking a monophasic combined oral contraceptive containing estetrol 15 mg and drospirenone 3 mg: an open-label observational study

Гинекология
Background. The choice of combined hormonal contraception in overweight women of reproductive age requires an assessment of not only contraceptive efficacy but also metabolic safety, as abdominal obesity, atherogenic dyslipidemia, insulin resistance, and
Natalia I. Sviridova, Sergey V. Nedogoda, Alla S. Salasyuk, Inna A. Deleske, Anastasiia D. Sviridova   +4 more
doaj   +1 more source

Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women

, 2014
Oral contraceptives (OCs) containing androgenic second and third generation progestins decrease insulin sensitivity (SI). In this study we investigated whether an oral contraceptive containing the anti-androgenic progestin drospirenone (DRSP) still ...
Piacenti, Ilaria, Zanin, Renata, Xholli A, CAGNACCI, Angelo, Zanin R, Cagnacci A, Tirelli, Alessandra, XHOLLI, ANJEZA, Tirelli A.   +8 more
core   +1 more source